Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Activiomics Signs Research Agreement with Kyowa Hakko Kirin

Published: Friday, November 23, 2012
Last Updated: Friday, November 23, 2012
Bookmark and Share
Company signs agreement as part of its strategic partnership with BioFocus.

Activiomics has announced that it has signed a research agreement with the Japanese pharmaceutical company Kyowa Hakko Kirin.

Under the agreement, Activiomics will apply its novel TIQUAS phosphoproteomics platform to elucidate signalling mechanisms of lead compounds in relevant cell-based systems.

This agreement was signed as part of Activiomics’ recently announced strategic partnership with BioFocus.

Activiomics partners with Pharma and Biotech using its innovative mass spectrometry based methods to analyze and interpret cell signalling pathway activity, generating high value information for the pharmaceutical and biotechnology industry.

“We’ve engaged with Activiomics because we recognize that Activiomics’ label free phosphoproteomics approach can provide unique insights into signalling pathway activity, information that can complement and extend our existing gene expression datasets. This technology will enable us to better understand cell signalling mechanisms of our lead compounds and could enable us to identify important biomarkers” said Etsuo Ohshima, Ph.D., managing officer and vice president, head, research division at Kyowa Hakko Kirin.

Dr Neil Torbett, COO of Activiomics, said: “We are delighted to have signed this agreement with Kyowa Hakko Kirin. This is a further endorsement of our technology platform and also represents Activiomics’ first entry into the Japanese market. Activiomics has received invaluable support from BioFocus in establishing this collaboration, a clear demonstration of our strategic partnership in action”.

Dr Chris Newton, Managing Director of BioFocus, commented “BioFocus is pleased to have participated in the signing of this deal, which we intend to be the first of many. Future deals will add together BioFocus’ drug discovery capabilities and Activiomics’ phosphoproteomics platform for the furtherance of our clients’ projects”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos